Topline revenue by quarter has largely flat-lined over the past five quarters:ĥ-Quarter Total Revenue (Seeking Alpha and The Author) Major competitive or other industry participants in various business areas of the firm include: The main drivers for this expected growth are a rise in chronic and infectious diseases combined with a growing elderly population worldwide that is more susceptible to immunological disorders from weakening immune systems.Īlso, an increased focus on personalized medicines as well as continued innovation by market participants will increase demand over the longer term. This represents a forecast CAGR of 4.8% from 2020 to 2027. OCDX's Market & CompetitionĪccording to a 2020 market research report by Allied Market Research, the global market for in vitro diagnostics was valued at an estimated $67.1 billion in 2019 and is expected to exceed $91 billion by 2027. The company pursues customers among clinical laboratories and said it sells to more than 70% of U.S. Transfusion Medicine - Donor Screening services before blood transfusions Management is headed by Chairman and CEO, Chris Smith, who has been with the firm since 2019 and was previously CEO of Cochlear Limited and previously held senior roles in a number of healthcare firms.īelow is a brief overview video of the firm's Covid-19 antibody tests:Ĭlinical Laboratories - Chemistry via in-vitro diagnostics Raritan, New Jersey-based Ortho Clinical was founded to develop a suite of services for clinical laboratories in hospitals in the U.S. Given these uncertainties, my outlook on OCDX at around $17.20 is a Hold. With the acquisition deal potentially on approval hold and Quidel's sharp stock price drop, the near-term future for OCDX is highly uncertain. The firm provides diagnostics services primarily to hospital labs in the U.S. Ortho Clinical Diagnostics ( OCDX) went public in January 2021, raising approximately $1.3 billion in gross proceeds from an IPO that was priced at $17.00 per share. Ortho Clinical Diagnostics Holdings plc was founded in 1939 and is headquartered in Raritan, New Jersey.Gorodenkoff/iStock via Getty Images A Quick Take On Ortho Clinical Diagnostics Holdings Its products are used in hospitals, laboratories, clinics, blood banks, and donor centers. The company is also involved in the provision of contract manufacturing and orthocare services. Its solutions include clinical chemistry and immunoassay instruments and tests to detect and monitor disease progression across a spectrum of therapeutic areas, including COVID-19 antibody and antigen tests and immunohematology instruments and tests for blood typing to ensure patient-donor compatibility in blood transfusions, as well as donor screening instruments and tests for blood and plasma screening for infectious diseases. The company offers automated instruments and assays, reagents, and other consumables that are used by these instruments to generate test results. Ortho Clinical Diagnostics Holdings plc provides in-vitro diagnostics solutions to the clinical laboratory and transfusion medicine communities worldwide.
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |